{"preliminary_commentary":{"by_channel":{"youtube":24,"podcast":12,"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01949805\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PROUD-PV","nct_id":"NCT01949805","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=proud-pv-nct01949805. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PROUD-PV","arms":[{"description":"Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD","label":"Hydroxyurea","type":"ACTIVE_COMPARATOR"},{"description":"Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection","label":"Peg-P-IFN-alpha-2b (AOP2014)","type":"EXPERIMENTAL"}],"collaborators":["PharmaEssentia (Co-Sponsor for USA)"],"completion_date":{"date":"2016-07","type":"ACTUAL"},"conditions":["Polycythemia Vera"],"enrollment":{"count":257,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Peg-P-IFN-alpha-2b (AOP2014)","otherNames":["AOP2014","P1101"],"type":"DRUG"},{"name":"Hydroxyurea","otherNames":["HU","Hydroxycarbamide","brand name Litalir (or other)"],"type":"DRUG"}],"last_update":"2016-11-28","lead_sponsor":"AOP Orphan Pharmaceuticals AG","official_title":"A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2016-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease response rate","timeFrame":"Month 12"}],"references":[{"citation":"Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.","pmid":"30287855","type":"DERIVED"}],"start_date":{"date":"2013-09"},"study_type":"INTERVENTIONAL","title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","url":"https://clinicaltrials.gov/study/NCT01949805"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/proud-pv-nct01949805"}